This study suggests that CXCL5 and CXCR2 inhibitors are attractive therapeutic targets that may have efficacy in treating or inhibiting the formation of metastatic bone tumors that are dependent on the CXCL5/CXCR2 signaling axis and resistant to current therapies. The gene discussed is CXCL5; the disease is bone neoplasm.